Skip to content
Inciteful Med

The Blueprint: Understanding the CFTR Gene and Diagnostic Testing

Last updated:

Cystic fibrosis is diagnosed using newborn screening, sweat chloride testing, and genetic tests. The sweat test is the gold standard, measuring salt levels on the skin. Identifying your specific CFTR gene mutation is crucial because it determines your eligibility for targeted treatments.

Key Takeaways

  • • Cystic fibrosis is caused by mutations in the CFTR gene, which provides instructions for a vital salt channel in your cells.
  • • The painless sweat chloride test is the gold standard for confirming a cystic fibrosis diagnosis.
  • • An inconclusive diagnosis (CFSPID or CRMS) means a child does not fully meet CF criteria but requires ongoing monitoring.
  • • Identifying your exact CFTR mutations is essential for accessing personalized treatments like CFTR modulators.

Understanding the biology of cystic fibrosis (CF) is the first step in taking charge of your health or your child’s care. At its core, CF is not just a lung disease; it is a “blueprint” issue that affects how cells throughout the body manage salt and water [1][2].

The Faulty Salt Channel: How CF Works

Every person has CFTR genes, which provide the instructions for making a protein called the CFTR protein [1]. Think of this protein as a salt channel—a tiny, gated gateway on the surface of your cells [3].

In a healthy body, these gateways open and close to let chloride (a component of salt) and bicarbonate flow out of the cell [3][4]. This flow is essential because:

  • Water Follows Salt: As salt moves out, water follows it, keeping the mucus on the outside of the cell thin and slippery [5].
  • pH Balance: Bicarbonate helps maintain the correct pH (acidity level), which allows the body’s natural defenses to work properly [4][6].

In someone with CF, these “gateways” are either broken, missing, or blocked [7][8]. Because chloride and bicarbonate can’t get out, water doesn’t follow. The result is mucus that becomes thick, sticky, and dehydrated, leading to blockages and an environment where bacteria can easily grow [5][3][9].

The Diagnostic Journey: Screening vs. Testing

It is important to distinguish between a screening and a diagnostic test. A screening (like the one done at birth) is designed to find anyone who might have a condition, while a diagnostic test confirms whether they actually do [10][11].

  1. Newborn Screening (NBS): Shortly after birth, a “heel prick” blood test measures levels of IRT (immunoreactive trypsinogen) [10]. High IRT levels can be a sign of CF, but they can also be caused by prematurity or a stressful birth, leading to “false positives” [12][13].
  2. Sweat Chloride Test: This is the “gold standard” for diagnosis [14]. It measures how much salt is in a person’s sweat. Because the CFTR protein doesn’t work correctly in the sweat ducts, people with CF have much higher levels of salt in their sweat [11]. This test is completely painless; it simply uses mild warmth and a specialized chemical to stimulate sweating on a small patch of skin [11].
    • Normal: Less than 30 mmol/L [15].
    • Intermediate: 30–59 mmol/L (requires further investigation) [15][16].
    • Indicative of CF: 60 mmol/L or higher [16][17].
  3. Genetic Testing: This test looks directly at the DNA to identify specific mutations in the CFTR gene [18]. To have a diagnosis of CF, a person typically must have two CF-causing mutations—one inherited from each parent [1].

When the Diagnosis is “Inconclusive” (CFSPID/CRMS)

Sometimes, a baby has a positive newborn screen, but their sweat test is in the “intermediate” range, or they only have one clear CF-causing mutation [19][20]. This is called CFSPID (Cystic Fibrosis Screen Positive, Inconclusive Diagnosis) or CRMS (CFTR-Related Metabolic Syndrome) [21].

If you receive this designation, it means your child does not currently meet the full criteria for CF [19]. While most of these children stay healthy, some may develop symptoms later in life or eventually transition to a formal CF diagnosis [22][23]. Regular follow-up with a CF specialist is essential to monitor their health over time [24][25].

Why Your Specific Mutation Matters

There are over 2,000 known mutations of the CFTR gene, and they are grouped into “classes” based on what is wrong with the protein gateway [7][8].

  • Class II (e.g., F508del): The most common mutation where the protein is misfolded and destroyed before it reaches the cell surface [7][26].
  • Class III: The gateway reaches the surface but won’t open [7].

Knowing your specific mutations is the key to personalized medicine. Modern CFTR modulators are designed to fix specific molecular errors [7][18]. For example, “triple-combination therapy” (like Trikafta) is specifically designed to help the F508del mutation fold correctly and then help the gateway stay open [27][28].

Completeness Checklist for Diagnosis

To ensure you have a clear picture of the diagnosis, check that the following steps have been completed:

  • [ ] Sweat Chloride Test: Performed at an accredited CF foundation center [14].
  • [ ] Genetic Panel: Identification of both CFTR mutations (if possible) [18].
  • [ ] Clinical Exam: Evaluation of symptoms in the lungs, pancreas, and digestive system [29].
  • [ ] Specialist Consultation: A meeting with a CF Care Team to discuss what the specific results mean for your future [30].

Frequently Asked Questions

What is a sweat chloride test for cystic fibrosis?
The sweat chloride test measures the amount of salt in a person's sweat. It is the gold standard for diagnosing cystic fibrosis, as people with the condition have much higher salt levels in their sweat due to a faulty CFTR protein.
What does an intermediate sweat test result mean?
An intermediate result falls between 30 and 59 mmol/L and requires further investigation. It may lead to an inconclusive diagnosis like CFSPID or CRMS, meaning the person does not fully meet the criteria for cystic fibrosis but requires regular monitoring.
Why is it important to know my specific CFTR mutation?
Knowing your exact genetic mutation helps determine your eligibility for personalized treatments called CFTR modulators. Medications like Trikafta are designed to target and fix specific molecular errors in the CFTR protein, such as the common F508del mutation.
What is the difference between newborn screening and a diagnostic test for CF?
A newborn screening checks for high IRT levels to identify babies who might have cystic fibrosis, but it can yield false positives. A diagnostic test, like the sweat chloride test or genetic testing, is required to confirm whether a person actually has the condition.

Questions for Your Doctor

  • • What are the two specific genetic mutations that were identified?
  • • Does my child (or do I) have a 'gating,' 'folding,' or 'protein synthesis' mutation?
  • • How do these specific mutations affect eligibility for CFTR modulators like Trikafta?
  • • If my sweat test result was in the 'intermediate' range, how often will we need to repeat the test?
  • • Who on the care team will help us monitor for symptoms if the diagnosis is currently 'inconclusive' (CFSPID/CRMS)?

Questions for You

  • • Do I have a copy of the genetic test results and the sweat chloride report for my records?
  • • How am I feeling about the 'uncertainty' of an inconclusive diagnosis, and do I need to talk to a counselor about it?
  • • Am I prepared to explain the difference between a screening result and a final diagnosis to my family or support system?
  • • What questions do I have about how these 'salt channels' affect different parts of the body beyond the lungs?

Want personalized information?

Type your question below to get evidence-based answers tailored to your situation.

References

  1. 1

    Ocular Changes in Cystic Fibrosis: A Review.

    Liberski S, Confalonieri F, Cofta S, et al.

    International journal of molecular sciences 2024; (25(12)) doi:10.3390/ijms25126692.

    PMID: 38928397
  2. 2

    [Evidence-based treatment of cystic fibrosis].

    Ringshausen FC, Hellmuth T, Dittrich AM

    Der Internist 2020; (61(12)):1212-1229 doi:10.1007/s00108-020-00896-9.

    PMID: 33201261
  3. 3

    The role of CFTR channel in female infertility.

    Habibullah MM

    Human fertility (Cambridge, England) 2023; (26(5)):1228-1237 doi:10.1080/14647273.2022.2161427.

    PMID: 36576330
  4. 4

    Is CFTR an exchanger?: Regulation of HCO3 -Transport and extracellular pH by CFTR.

    Massey MK, Reiterman MJ, Mourad J, Luckie DB

    Biochemistry and biophysics reports 2021; (25()):100863 doi:10.1016/j.bbrep.2020.100863.

    PMID: 33376814
  5. 5

    Pharmacological and Genomic Approaches in Management of Cystic Fibrosis.

    Qadir MI, Yameen IA

    Critical reviews in eukaryotic gene expression 2020; (30(3)):191-197 doi:10.1615/CritRevEukaryotGeneExpr.2020030845.

    PMID: 32749105
  6. 6

    Unified Airway-Cystic Fibrosis.

    Cho DY, Grayson JW, Woodworth BA

    Otolaryngologic clinics of North America 2023; (56(1)):125-136 doi:10.1016/j.otc.2022.09.009.

    PMID: 36266104
  7. 7

    Precision Medicine Based on CFTR Genotype for People with Cystic Fibrosis.

    Haq I, Almulhem M, Soars S, et al.

    Pharmacogenomics and personalized medicine 2022; (15()):91-104 doi:10.2147/PGPM.S245603.

    PMID: 35153502
  8. 8

    Emerging Cystic Fibrosis Transmembrane Conductance Regulator Modulators as New Drugs for Cystic Fibrosis: A Portrait of in Vitro Pharmacology and Clinical Translation.

    Ghelani DP, Schneider-Futschik EK

    ACS pharmacology & translational science 2020; (3(1)):4-10 doi:10.1021/acsptsci.9b00060.

    PMID: 32259083
  9. 9

    Hydrator Therapies for Chronic Bronchitis. Lessons from Cystic Fibrosis.

    Bennett WD, Henderson AG, Donaldson SH

    Annals of the American Thoracic Society 2016; (13 Suppl 2()):S186-90 doi:10.1513/AnnalsATS.201509-652KV.

    PMID: 27115955
  10. 10

    False-Positive and False-Negative Sweat Tests: Systematic Review of the Evidence.

    Guglani L, Stabel D, Weiner DJ

    Pediatric allergy, immunology, and pulmonology 2015; (28(4)):198-211 doi:10.1089/ped.2015.0552.

    PMID: 35923002
  11. 11

    Uncommon clinical presentation of cystic fibrosis in a patient homozygous for a rare CFTR mutation: a case report.

    Jaworska J, Marach-Mocarska A, Sands D

    BMC pediatrics 2020; (20(1)):90 doi:10.1186/s12887-020-1980-y.

    PMID: 32103733
  12. 12

    The first five-year evaluation of cystic fibrosis neonatal screening program in São Paulo State, Brazil.

    Maciel LMZ, Magalhães PKR, Ciampo IRLD, et al.

    Cadernos de saude publica 2020; (36(10)):e00049719 doi:10.1590/0102-311X00049719.

    PMID: 33111836
  13. 13

    Intra-individual biological variation in sweat chloride concentrations in CF, CFTR dysfunction, and healthy pediatric subjects.

    Cirilli N, Raia V, Rocco I, et al.

    Pediatric pulmonology 2018; (53(6)):728-734 doi:10.1002/ppul.23992.

    PMID: 29611353
  14. 14

    Dried Blood Spot-Based Metabolomic Profiling in Adults with Cystic Fibrosis.

    Al-Qahtani W, Abdel Jabar M, Masood A, et al.

    Journal of proteome research 2020; (19(6)):2346-2357 doi:10.1021/acs.jproteome.0c00031.

    PMID: 32312052
  15. 15

    Australasian guideline for the performance of sweat chloride testing 3rd edition: to support cystic fibrosis screening, diagnosis and monitoring.

    Massie J, McWhinney A, Greed L, et al.

    Clinical chemistry and laboratory medicine 2025; (63(10)):1956-1964 doi:10.1515/cclm-2025-0433.

    PMID: 40476459
  16. 16

    Revisiting sweat chloride test results based on recent guidelines for diagnosis of cystic fibrosis.

    Pagaduan JV, Ali M, Dowlin M, et al.

    Practical laboratory medicine 2018; (10()):34-37 doi:10.1016/j.plabm.2018.01.001.

    PMID: 29326970
  17. 17

    Diagnosis of Cystic Fibrosis: Consensus Guidelines from the Cystic Fibrosis Foundation.

    Farrell PM, White TB, Ren CL, et al.

    The Journal of pediatrics 2017; (181S()):S4-S15.e1 doi:10.1016/j.jpeds.2016.09.064.

    PMID: 28129811
  18. 18

    Screening by high-throughput sequencing for pathogenic variants in cystic fibrosis: Benefit of introducing personalized therapies.

    de Melo ACV, de Souza KSC, da Silva HPV, et al.

    Journal of cellular and molecular medicine 2022; (26(23)):5943-5947 doi:10.1111/jcmm.17605.

    PMID: 36369753
  19. 19

    Cystic fibrosis transmembrane conductance regulator-related metabolic syndrome/cystic fibrosis screen positive, inconclusive diagnosis (CRMS/CFSPID).

    Sinha A, Southern KW

    Breathe (Sheffield, England) 2021; (17(3)):210088 doi:10.1183/20734735.0088-2021.

    PMID: 35035555
  20. 20

    Children with cystic fibrosis are still receiving inconclusive diagnosis despite undergoing newborn screening.

    Loukou I, Moustaki M, Douros K

    Acta paediatrica (Oslo, Norway : 1992) 2023; (112(10)):2039-2044 doi:10.1111/apa.16949.

    PMID: 37602754
  21. 21

    Inconclusive Diagnosis after Newborn Screening for Cystic Fibrosis.

    Munck A

    International journal of neonatal screening 2020; (6(1)):19.

    PMID: 33073016
  22. 22

    Evaluating CRMS/CFSPID phenotypes and outcomes: A retrospective study from a large UK cystic fibrosis centre.

    Mansfield A, Hine C, Nagakumar P, et al.

    Heliyon 2024; (10(21)):e39935 doi:10.1016/j.heliyon.2024.e39935.

    PMID: 39553608
  23. 23

    Outcomes of early repeat sweat testing in infants with cystic fibrosis transmembrane conductance regulator-related metabolic syndrome/CF screen-positive, inconclusive diagnosis.

    Terlizzi V, Claut L, Colombo C, et al.

    Pediatric pulmonology 2021; (56(12)):3785-3791 doi:10.1002/ppul.25683.

    PMID: 34549893
  24. 24

    Cystic Fibrosis Foundation Evidence-Based Guideline for the Management of CRMS/CFSPID.

    Green DM, Lahiri T, Raraigh KS, et al.

    Pediatrics 2024; (153(5)) doi:10.1542/peds.2023-064657.

    PMID: 38577740
  25. 25

    Outcomes of children with cystic fibrosis screen positive, inconclusive diagnosis/CFTR related metabolic syndrome.

    Gunnett MA, Baker E, Mims C, et al.

    Frontiers in pediatrics 2023; (11()):1127659 doi:10.3389/fped.2023.1127659.

    PMID: 36969284
  26. 26

    Lumacaftor alone and combined with ivacaftor: preclinical and clinical trial experience of F508del CFTR correction.

    Brewington JJ, McPhail GL, Clancy JP

    Expert review of respiratory medicine 2016; (10(1)):5-17 doi:10.1586/17476348.2016.1122527.

    PMID: 26581802
  27. 27

    Discovery and Development of CFTR Modulators for the Treatment of Cystic Fibrosis.

    Wang X, Tse C, Singh A

    Journal of medicinal chemistry 2025; (68(3)):2255-2300 doi:10.1021/acs.jmedchem.4c02547.

    PMID: 39882833
  28. 28

    Molecular structures reveal synergistic rescue of Δ508 CFTR by Trikafta modulators.

    Fiedorczuk K, Chen J

    Science (New York, N.Y.) 2022; (378(6617)):284-290 doi:10.1126/science.ade2216.

    PMID: 36264792
  29. 29

    [Cystic fibrosis in childhood and adulthood].

    Syunyaeva Z, Mall MA, Stahl M

    Innere Medizin (Heidelberg, Germany) 2024; (65(6)):538-544 doi:10.1007/s00108-024-01717-z.

    PMID: 38714556
  30. 30

    Newborn Screening for CF across the Globe-Where Is It Worthwhile?

    Scotet V, Gutierrez H, Farrell PM

    International journal of neonatal screening 2020; (6(1)):18.

    PMID: 33073015

This page is for educational purposes only and does not replace professional medical advice. Always discuss your diagnostic tests, sweat test results, and genetic testing with your cystic fibrosis care team.

Stay up to date

Get notified when new research about Cystic fibrosis is published.

No spam. Unsubscribe anytime.